Lenalidomida Zentiva

Lenalidomide, the active ingredient in Lenalidomida Zentiva, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes and mantle‑cell lymphoma in adult patients for whom it is clinically appropriate.

GNH USA supplies Lenalidomida Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomida Zentiva is an immunomodulatory agent used in hematologic malignancies and related disorders.

- Multiple Myeloma: improves disease control and prolongs progression‑free survival. - Myelodysplastic Syndromes: reduces transfusion dependence and delays transformation to acute leukemia. - Mantle Cell Lymphoma: contributes to tumor reduction and extends overall survival.

Lenalidomida Zentiva may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels causing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Constipation: difficulty passing stools. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver enzyme elevation or dysfunction. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters regularly. - Pregnancy: contraindicated (Category X); ensure effective contraception. - Thrombosis risk: assess need for prophylactic anticoagulation. - Hematologic monitoring: perform complete blood counts weekly initially. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic dysfunction: monitor liver enzymes and adjust as needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lenalidomida Zentiva can interact with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Thalidomide or other IMiDs: increased risk of overlapping toxicities. - Live vaccines: potential for reduced vaccine efficacy and infection.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance bleeding risk; monitor INR. - NSAIDs: increase risk of renal impairment; assess renal function. - Digoxin: possible alteration of serum levels; check concentrations regularly.